MedTrace Logo

Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

NCT01204164 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2016-05-06

No results posted yet for this study

Summary

This is a multicenter, open-label, dose escalation Phase 1 study.

Conditions

Interventions

DRUG

TG02 citrate

TG02 citrate capsules given orally.

DRUG

Carfilzomib

Carfilzomib per PI

DRUG

Dexamethasone

Dexamethasone (Oral or IV)

Sponsors & Collaborators

  • Tragara Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • T Parrott · Tragara Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2016-03-31
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01204164 on ClinicalTrials.gov